Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2022 08:00 ET | Source: Vitalis Pharmaceuticals

Randomized Controlled Study Supports Vitalis Analgesic’s Oral Ketamine as a Potential Treatment of Acute Pain

Study published online in American Journal of Emergency Medicine (https://doi.org/10.1016/j.ajem.2022.05.026) NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- Vitalis Analgesics LLC, a specialty...
May 26, 2022 08:00 ET | Source: Vitalis Pharmaceuticals

Vitalis Analgesics Announces Publication of Pilot Study Evaluating A Novel Oral Ketamine and Aspirin Formulation for Acute Musculoskeletal Pain

Treatment showed improved pain scores with lower side effects than typically seen with ketamine Supports evaluation of proprietary VTS-85, an oral formulation of ketamine and aspirin ...
January 12, 2021 08:00 ET | Source: Vitalis Pharmaceuticals

First Patient Dosed in Pilot Study of Vitalis’ VTS-K for Acute Musculoskeletal Pain

Vitalis’ proprietary oral formulation of ketamine and aspirin in development for treatment of acute painTop-line Data Expected First Quarter 2021 NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vitalis...
September 01, 2020 08:00 ET | Source: Vitalis Pharmaceuticals

Vitalis to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Vitalis LLC, a specialty pharmaceutical company leveraging its proprietary VTS platform to overcome the limitations of existing drugs and enhance patient...
April 21, 2020 08:00 ET | Source: Vitalis Pharmaceuticals

Vitalis Receives Orphan Drug Designation for Diroximel Fumarate and Monomethyl Fumarate, in Combination with VTS-Aspirin, for Multiple Sclerosis Patients Who Experience Fumarate Flush

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- Vitalis LLC, a specialty pharmaceutical company leveraging its proprietary VTS-Aspirin platform to overcome the limitations of existing drugs and enhance...
January 07, 2020 08:00 ET | Source: Vitalis Pharmaceuticals

Vitalis Pharmaceuticals Announces Results of Type C Meeting with FDA for VTS-72

Phase 3 Study Expected to Initiate in 2020, with Potential for First New Drug Application in Acute Flush in Multiple Sclerosis (MS) Patients in First Half 2021 Company plans to extend clinical...
October 22, 2019 08:00 ET | Source: Vitalis Pharmaceuticals

Vitalis Pharmaceuticals Anticipates Launch of Novel Low-Flush Fumarate by 2021

VTS-72 designed to improve pharmacokinetics and alleviate the Fumarate Flush; highly prevalent side effect of fumarate therapy NDA submission as early as 2020, followed by potential launch into $4...